News
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026. Consolidated sales totaled €984 million in the first quarter of 2026.
Swipe to discover more
-
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries
bioMérieux, a world leader in in vitro diagnostics, announces the publication of a multi-country health economic analysis assessing the impact of deploying fast identification and antimicrobial susceptibility testing (ID/AST) early in the care pathway for patients with bloodstream infections at high-risk of sepsis. -
Why participatory approaches for AMR matters to people and patient-centered action
Antimicrobial Resistance (AMR) is a term that is not widely recognised by many people globally. What’s even more concerning is that those who are most affected by AMR—patients and their families—are often the ones who lack that awareness and rely on understanding its consequences. -
Food Safety Trends Building Momentum into 2026
As 2026 begins, bioMérieux proudly continues our tradition of looking into the next twelve months and analyzing how key food safety trends will influence the food supply chain and our partners’ operations. The three identified trends for 2026 will continue to develop and inform food safety and quality standards — standards that we at bioMérieux are proud to help pioneer and contribute to.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19